Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Botanix Pharmaceuticals Limited
  6. Summary
    BOT   AU000000BOT2

BOTANIX PHARMACEUTICALS LIMITED

(BOT)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/25 12:10:15 am
0.06 AUD   --.--%
01/202022 EDISON OPEN HOUSE : Global Healthcare
PU
01/13BOTANIX PHARMACEUTICALS : DEAL NEWS | Pfizer enters CBD market
PU
2021AMR : the next global pandemic?
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
0.072(c) 0.069(c) 0.068(c) 0.064(c) 0.06(c) Last
1 014 875 516 587 735 169 1 253 806 1 696 854 Volume
-1.37% -4.17% -1.45% -5.88% -6.25% Change
More quotes
Estimated financial data (e)
Sales 2020 7,57 M 5,42 M 5,42 M
Net income 2020 -16,7 M -12,0 M -12,0 M
Net cash position 2020 24,2 M 17,3 M 17,3 M
P/E ratio 2020 -2,18x
Yield 2020 -
Sales 2021 6,89 M 4,93 M 4,93 M
Net income 2021 -3,33 M -2,39 M -2,39 M
Net cash position 2021 21,3 M 15,3 M 15,3 M
P/E ratio 2021 -23,4x
Yield 2021 -
Capitalization 58,4 M 41,7 M 41,8 M
EV / Sales 2020 1,81x
EV / Sales 2021 8,21x
Nbr of Employees -
Free-Float -
More Financials
Company
Botanix Pharmaceuticals Limited is a clinical-stage synthetic cannabinoid pharmaceutical company focuses on the development of dermatology and antimicrobial products. The Company's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for... 
Sector
Pharmaceuticals
Calendar
02/28Earnings Release
More about the company
All news about BOTANIX PHARMACEUTICALS LIMITED
01/202022 EDISON OPEN HOUSE : Global Healthcare
PU
01/13BOTANIX PHARMACEUTICALS : DEAL NEWS | Pfizer enters CBD market
PU
2021AMR : the next global pandemic?
PU
2021BOTANIX PHARMACEUTICALS : Investor Roadshow Presentation
PU
2021BOTANIX PHARMACEUTICALS : Roadshow Presentation
PU
2021BOTANIX PHARMACEUTICALS : ANTIMICROBIAL AWARENESS WEEK 18-24 November 2021
PU
2021BOTANIX PHARMACEUTICALS : MEET THE TEAM | Lynda Berne, Head of Commercial
PU
2021BOTANIX PHARMACEUTICALS : Says Skin Condition Canine Study Underway; Shares Up More than 4..
MT
2021Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program
CI
2021Botanix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 3..
CI
2021Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study
CI
2021BOTANIX PHARMACEUTICALS : Identifies New Indication for Antimicrobial Platform
MT
2021BOTANIX PHARMACEUTICALS : Receives Ethics Approval for Rosacea Skin Disease Study
MT
2021Botanix Pharmaceuticals Limited Announces BTX 1702 Rosacea Study Approval
CI
2021BOTANIX PHARMACEUTICALS : Expands Management Team
MT
More news
News in other languages on BOTANIX PHARMACEUTICALS LIMITED
2021Botanix Pharmaceuticals déclare qu'une étude sur les affections cutanées chez les chien..
2021Botanix Pharmaceuticals identifie une nouvelle indication pour sa plateforme antimicrob..
2021Botanix Pharmaceuticals élargit son équipe de direction
2021L'onguent expérimental BTX 1801 de Botanix Pharmaceuticals obtient des résultats positi..
2021Une revue évaluée par des pairs publie des données sur le programme antimicrobien de Bo..
More news
Chart BOTANIX PHARMACEUTICALS LIMITED
Duration : Period :
Botanix Pharmaceuticals Limited Technical Analysis Chart | BOT | AU000000BOT2 | MarketScreener
Technical analysis trends BOTANIX PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Vincent P. Ippolito Executive Chairman & President
H. Bill Bosch Executive Director & Chief Scientific Officer
Clarence L. Young Chief Medical Officer
Stewart James Washer Non-Executive Director
Matthew Callahan Executive Director
Sector and Competitors